{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T05:15:16Z","timestamp":1763442916421,"version":"3.45.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The high cost of anticancer drugs has raised concerns due to the financial burden on patients and pressure on healthcare systems. We examine the relation between pricing premiums, price revision, and clinical value for anticancer drugs approved in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included anticancer drugs approved in Japan from 2013 to 2023. Differences in clinical value, as measured by the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS), among drugs receiving different premium proportions, were analyzed using the Mann-Whitney U test. Pearson correlation coefficients were calculated between treatment costs and clinical outcomes and value, including progression-free survival (PFS) gain, overall survival (OS) gain, objective response rate (ORR) gain and ESMO-MCBS. We also compared the magnitude of price revisions and price reductions with different clinical values. We used regression analysis to explore the association between clinical value, price revision, and influencing factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our cohort included 94 anticancer drugs and 119 key clinical trials. 39 drugs (41.49%) received premium pricing, while 55 drugs (58.51%) did not. Drugs with pricing premiums had higher ESMO scores than those without (3 vs. 2; P = 0.0013), with ESMO scores showing an increasing trend as the proportion of additional scores rose. Pearson correlation analysis revealed no significant association between daily treatment cost and ESMO score (r = 0.025, P = 0.79), PFS gain (r = \u22120.12, P = 0.37), OS gain (r = \u22120.25, P = 0.066), or ORR gain (r = 0.049, P = 0.8). Additionally, no significant differences were observed between high clinical value drugs (ESMO = 4\u20135) and low-to-medium clinical value drugs (ESMO = 1\u20133) in median price revision percentage and median price reduction percentage (\u22120.02% vs. 0.00%, P = 0.65; \u22129.86% vs. \u221213.55%, P = 0.607). Moreover, multivariate linear regression analysis revealed no association between ESMO scores, premium proportion, PFS gain, OS gain, ORR gain, approval year (P = 0.32; P = 0.06; P = 0.71; P = 0.06; P = 0.50; P = 0.51).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our study found that Japan\u2019s price premium reflects clinical value and provides incentives for high-clinical-value anticancer drugs. However, during both initial pricing and subsequent revision phases, there is room for improvement in aligning drug prices with clinical value. Policymakers should further refine pricing and revision systems to more effectively promote clinical value-driven drug pricing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1641775","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T05:12:46Z","timestamp":1763442766000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pricing, price revision, and clinical value of anticancer drugs in Japan: a retrospective observational study"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiaqi","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibo","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jval.2019.04.1918","article-title":"Current policy and practice for value-based pricing","volume":"22","author":"Augustovski","year":"2019","journal-title":"Value Health"},{"key":"B2","doi-asserted-by":"publisher","first-page":"04140","DOI":"10.7189\/jogh.13.04140","article-title":"The correlation between the costs and clinical benefits of national price-negotiated anticancer drugs for specific cancers in China","volume":"13","author":"Bao","year":"2023","journal-title":"J. Glob. Health"},{"key":"B3","unstructured":"Drug lag and loss: japan\u2019s prescription for progress | British chamber of commerce in Japan\n          \n          \n          2025"},{"key":"B4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1001\/jama.2018.11808","article-title":"Defining value-based pricing of drugs","volume":"320","author":"Broder","year":"2018","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"100625","DOI":"10.1016\/j.eclinm.2020.100625","article-title":"Cost-effectiveness of cancer drugs: comparative analysis of the United States and England","author":"Cherla","year":"2020","journal-title":"EClinicalMedicine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1744133124000288","article-title":"Reimbursement prices of new, innovative medicines in Germany: a comparison of negotiation and cost-effectiveness analysis","author":"Gandjour","year":"2025","journal-title":"HEPL"},{"key":"B8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1257\/jep.29.1.139","article-title":"Pricing in the market for anticancer drugs","volume":"29","author":"Howard","year":"2015","journal-title":"J. Econ. Perspect."},{"key":"B9","unstructured":"Global oncology trends 2024: outlook to 2028\n          \n          \n          2024"},{"key":"B10","doi-asserted-by":"publisher","first-page":"101212","DOI":"10.1016\/j.lanwpc.2024.101212","article-title":"Challenges introduced by Japan\u2019s drug pricing policy","volume":"51","author":"Kinoshita","year":"2024","journal-title":"Lancet Regional Health - West. Pac."},{"key":"B11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12962-023-00441-z","article-title":"Generic drug crisis in Japan and changes leading to the collapse of universal health insurance established in 1961: the case of Kobayashi Kako co. Ltd","volume":"21","author":"Kosaka","year":"2023","journal-title":"Cost Eff. Resour. Allocation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.31662\/jmaj.2018-0016","article-title":"Health policy in Japan - current situation and future challenges","volume":"2","author":"Matsuda","year":"2019","journal-title":"JMA J."},{"key":"B13","unstructured":"List of new pharmaceuticals (scheduled for inclusion on 25 May 2016)\n          \n          \n          2016"},{"key":"B14","unstructured":"Update of drug pricing system in Japan\n          \n          \n          2018"},{"key":"B15","unstructured":"Regarding the 2022 pharmaceutical Price system reform\n          \n          \n          2022"},{"key":"B16","unstructured":"Research on quantitative calculation methods for the premium rates of breakthrough and usefulness premiums in drug price calculation standards\n          \n          \n          2023"},{"key":"B17","unstructured":"List of new Pharmaceuticals (scheduled for inclusion on 22 May 2024)\n          \n          \n          2024"},{"key":"B18","unstructured":"Guidelines for drug price calculation (15 February 2023 no. 215002)"},{"key":"B19","unstructured":"Japan's NHl drug price system"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.jval.2023.06.020","article-title":"Cancer drug prices in the United States: efficacy, innovation, clinical trial evidence, and epidemiology","volume":"26","author":"Michaeli","year":"2023","journal-title":"Value Health"},{"key":"B21","doi-asserted-by":"publisher","first-page":"101088","DOI":"10.1016\/j.lanwpc.2024.101088","article-title":"List prices and clinical value of anticancer drugs in China, Japan, and South Korea: a retrospective comparative study","volume":"47","author":"Pan","year":"2024","journal-title":"Lancet Regional Health - West. Pac."},{"key":"B22","unstructured":"Over 2,000 drugs in Japan undergo an average price reduction of 9.4% in April\n          \n          \n          2023"},{"key":"B23","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrclinonc.2017.31","article-title":"The high price of anticancer drugs: origins, implications, barriers, solutions","volume":"14","author":"Prasad","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1200\/JCO.1998.16.7.2297","article-title":"Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?","volume":"16","author":"Ratain","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1001\/jama.2018.5367","article-title":"Value-based pricing and patient access for specialty drugs","volume":"319","author":"Robinson","year":"2018","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1111\/cas.13831","article-title":"Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan","volume":"109","author":"Satoh","year":"2018","journal-title":"Cancer Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1017\/S0266462320000264","article-title":"Cost-effectiveness evaluation for pricing medicines and devices: a new value-based price adjustment system in Japan","volume":"36","author":"Shiroiwa","year":"2020","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"B28","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1177\/2168479017706716","article-title":"Comparison of new drug accessibility and price between Japan and major European countries","volume":"51","author":"Takayama","year":"2017","journal-title":"Ther. Innov. Regul. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S1470-2045(20)30139-X","article-title":"Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis","volume":"21","author":"Vokinger","year":"2020","journal-title":"Lancet Oncol."},{"key":"B30","unstructured":"Technical report on pricing of cancer medicines and its impacts\n          \n          \n          2019"},{"key":"B31","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40273-022-01161-7","article-title":"Prices and clinical benefit of national price-negotiated anticancer medicines in China","volume":"40","author":"Zhang","year":"2022","journal-title":"PharmacoEconomics"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1641775\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T05:12:48Z","timestamp":1763442768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1641775\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":31,"alternative-id":["10.3389\/fphar.2025.1641775"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1641775","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"article-number":"1641775"}}